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Prescription dose was 36-75Gy in 3-6 fractions. SBRT was 
delivered using the volumetric modulated arc therapy 
technique with flattening filter free photon beams. The 
primary end points of this study were in–field local control 
(LC) and toxicity. Secondary end points were overall survival 
(OS) and progression free survival (PFS).  
Results: 43 patients with 63 HCC lesions were irradiated. All 
patients had Child-Turcotte-Pugh class A or B disease. Median 
follow-up was 8 months (range 3-43 months). Actuarial LC at 
1 and 2years was 86% and 64%. An Equivalent Dose >100Gy 
and GTV size were significant prognostic factors for LC in 
univariate analysis (p<0.001 and p<0.02). Median OS was 18 
months. Actuarial OS at 1 and 2 years was 78% and 45%, 
respectively. Univariate analysis showed that OS is correlated 
with LC (p<0.04), BED>100 (p<0.05) and Cumulative GTV<5cm 
(p<0.04). Median PFS was 8 months, with a 1-year PFS rate of 
41%. Grade ≥3 toxicity was observed in 7 patients (16%). No 
classic RILD was observed. 
Conclusions: Our study show that SBRT is a safe and effective 
treatment for selected patients with inoperable HCC. Local 
control rates and toxicity profile were encouraging.  
   
PO-0711   
Prediction of response to neoadjuvant chemotherapy 
followed by chemoradiotherapy in rectal cancer by MRI 
volumetry 
T. Seierstad1, K.H. Hole1, K.K. Grøholt2, S. Dueland3, A.H. 
Ree4, K. Flatmark5, K. Røe4 
1Oslo University Hospital, Department of Radiology and 
Nuclear Medicine, Oslo, Norway  
2Oslo University Hospital, Department of Pathology, Oslo, 
Norway  
3Oslo University Hospital, Department of Oncology, Oslo, 
Norway  
4Akershus University Hospital, Department of Oncology, Oslo, 
Norway  
5Oslo University Hospital, Department of Gastroenterological 
Surgery, Oslo, Norway  
 
Purpose/Objective: Chemoradiotherapy (CRT) followed by 
complete surgical removal is regarded as standard of care for 
locally advanced rectal cancer (LARC). To further improve 
clinical outcome therapeutic approaches may incorporate 
additional agents to the standard fluorouracil (FU)-based 
CRT. Intensified preoperative treatment with systemic 
neoadjuvant chemotherapy (NACT) before conventional long-
course CRT has shown promising long-term outcome and 
acceptable safety profiles. However, at present, it remains 
challenging to reliably identify good and poor responders at 
an early stage in order to achieve more individualized, 
effective and less toxic treatment of these patients. In this 
study, the purpose was to investigate if magnetic resonance 
imaging (MRI)-assessed tumor volumetry predicts histologic 
tumor response to NACT and subsequent CRT in LARC. 
Materials and Methods: The treatment in this experimental 
study consisted of two cycles of bolus 5-FU and oxaliplatin 
followed by long-course radiotherapy delivered 
concomitantly with capecitabine and oxaliplatin, before 
radical surgery. Complete MRI data sets and tumor 
histopathology from 69 prospectively enrolled patients were 
analyzed. Whole-tumor volumes were contoured in T2-
weighted MR images obtained pretreatment (VPRE), after 
NACT (VNACT), and after the full course of NACT followed by 
CRT (VCRT). VPRE, VNACT, and tumor volume changes relative to 
VPRE, DVNACT and DVCRT, were calculated and correlated to 
histologic tumor regression grade (TRG). 
Results: In total, 61% of good histologic responders (TRG 1-2) 
to NACT followed by CRT were correctly predicted by small 
pretreatment tumor volumes (VPRE < 10.5 cm3), large volume 
regressions after NACT (DVNACT > -78.2%), or small tumor 
volumes after NACT (VNACT < 3.3 cm3). Small pretreatment 
volume and large volume regression after NACT identified 
different patients; only six patients had both small 
pretreatment volume and large volume regression. Small 
tumor volume after NACT identified the majority of good 
responders (n = 27), with a sensitivity of 55.1% and a 
specificity of 100% (area under curve = 0.84), although the 
combined use of all three volumetric measurements 
identified the most. The volume regression after completed 
NACT and CRT (VCRT) was not significantly different between 
good and poor responders (TRG 1-2 versus TRG 3-5).  
Conclusions: MRI-assessed small tumor volumes following 
NACT, before the commencement of CRT, predicted good 
histologic tumor response (TRG1-2) to the completed course 
of NACT and CRT with high accuracy. Further, the combined 
use of tumor volume measurements before, during, and after 
NACT identified most good responders. MR volumetry may be 
used to improve individualized, multimodal treatment of 
LARC. 
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Purpose/Objective: To evaluate the role of 3T 
multiparametric MRI (3TmMRI) without endo-rectal coil (ERC) 
in the detection of radiographic local recurrences (rLR) in a 
contemporary cohort of patients with prostate cancer treated 
at our hospital and who presented a biochemical recurrence 
after PR with low PSA levels and to identify clinical 
parameters associated with the findings of the 3TmMRI.  
Materials and Methods: Between 2009 and 2013, 57 patients 
with biochemical recurrence after RP of a PC and considered 
for salvage radiation therapy (SRT) were included. 3TmMRI 
with T2-weighted imaging (T2WI), diffusion weighted imaging 
(DWI) and dynamic contrast-enhanced images (DCE) without 
ERC was carried out in all the patients prior to treatment. 
Given that there are no validated criteria, a points system 
was established to define the findings of the 3TmMRI, 0 being 
(normal; no abnormality was observed in the MRI sequences: 
T2WI, DWI or DCE), 1 being (doubtful; an abnormality was 
detected in one of the MRI sequences, with no correlation in 
the rest of the sequences) and 2 being (abnormal; 
abnormality detected in all or in two of the sequences). The 
local relapse was defined as 2. To analyze the relationship 
3rd ESTRO Forum 2015                                                                                                                                         S351 
 
between rLR in 3TmMRI and the clinical variables, a logistic 
regression analysis was carried out. 
Results: In 14/57 patients (24.56%) a rLR through 3TmMRI 
was detected. Median pre-SRT PSA was 0.40 ng/ml 
(interquartile range, 0.30-2.05 ng/ml). The location of the 
recurrence was perianastomotic in 8/14 patients (57.14%) 
and retrovesical in 6/14 patients (42.86%). The median size 
of the local recurrence was 15.2 mm (range, 8.0-46.0 mm). 
The median apparent diffusion coefficient (ADC) value on 
DWI was 0.90 mm2/s (range, 0.35-1.58 mm2/s) and 6/14 
patients (42.85%) presented type 3 pathological captation 
curves and 3/14 patients (21.42%) presented type 2 
enhancement curves in the DCE images. Normal prostate 
tissue remains were identified in 9/57 patients (15.78%). 
Pelvic nodal recurrence was evidenced in 4/57 patients 
(7.01%) and pelvic bone metastasis were found in 4/57 
patients (7.01%). 12.90% (4/31) rLR was observed in patients 
with PSA ≤0.5 ng/ml, vs 38.46% (10/26) for PSA>0.5 ng/ml. 
The incidence of rLR according to PSA doubling time (PSADT) 
was 15.% (6/40) for PSADT≤14 months, vs 54.54% (6/11) for 
PSADT>14 months. The probability of rLR was significantly 
higher in patients with PSA levels >0.5 ng/ml (adjusted odds 
ratio (OR): 6.25; 95% confidence interval (CI): 1.27-
30.79;p=0.02), or PSA doubling time (PSADT)>14 months 
(adjusted OR: 7.12; 95% CI:1.40-36.25; p=0.01). 
Conclusions: This is the first study to find a significant 
relationship between the PSADT and the rLR through MRI. 
Patients that benefit most from conducting a 3TmMRI were 
those with PSADT>14 months or with pre-SRT PSA >0.5 ng/ml. 
Its routine use could have significant clinical implications in 
SRT.  
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Purpose/Objective: To eradicate all clonogenic cells within 
the gross tumor volume (GTV) and subclinical malignant 
disease area (CTV), for most cancers different radiation doses 
are prescribed to these volumes. This paradigm is however 
not routinely applied in prostate cancer. The entire gland is 
typically treated as GTV to a conventional dose of 78 Gy. 
Here, in higher risk patients, the treatment results are not 
sufficient, yet associated with mild to severe normal tissue 
toxicity. Derived from the histopathological properties, we 
propose to differentiate the dose between GTV and the CTV 
in the treatment of prostate cancer in order to increase the 
treatment results as well as reduce the risk of the treatment-
related toxicity.  
Materials and Methods: Twenty-five radical prostatectomy 
specimens were studied. The largest tumor focus was defined 
as index lesion. All index lesions and satellite tumor lesions 
≥0.5cm3 were set as GTV. The CTV was characterized as the 
whole gland excluding the GTV. Volume, cell density and 
Gleason score of index and satellite lesions were determined. 
This information was incorporated into radiobiological 
modeling of dose differentiation between GTV and CTV for 
these patients simulating the situation as if they were 
treated with radiotherapy. The tumor control probability 
(TCP) was modeled by assuming either a homogeneous or a 
heterogeneous α according to histopathological properties of 
tumor foci. For an α/β of 3, we chose the value for the 
homogeneous α (αhom) such that 80% TCP was reached in our 
population with a conventional dose of 78 Gy. The 
heterogeneous α varied with Gleason grade, keeping the 
weighted average over all tumors and Gleason grades equal 
to αhom. 
 
Results: 
 
 
Multifocal cancer was found in 76% (19/25) of the cases. The 
CTV of 12 cases of multifocal cancers (12/19) contained 
advanced pathology of GS 4+3 or 4+4. Compared to the GTV 
however, the pathology of CTV was on average more 
favorable. We found αhom=0.17 Gy-1 to reach 80% TCP with a 
conventional dose of 78 Gy. Here, a GTV dose of 81 Gy could 
be combined with a dose reduction to the CTV to 71 Gy 
without compromising the TCP in the population (Figure1a). 
Using a heterogeneous α however, α=0.212, 0.162 and 0.112 
Gy-1 for Gleason patterns 3, 4 and 5 respectively, a GTV dose 
of 89 Gy could be combined with a 70 Gy dose to the CTV 
while maintaining a TCP of 80% in the population (Figure1b). 
Conclusions: As subclinical prostate tumor foci may be 
clinically relevant, these need to be treated as CTV. If a 
homogeneous radiosensitivity for all tumor foci is considered, 
dose differentiation between GTV and CTV in the order of 10 
Gy may be feasible. Further dose differentiation can be 
achieved if Gleason grades are related to a heterogeneity in 
the radiosensitivity of the tumor foci. This may reduce the 
risk of the treatment-related toxicity without compromising 
local control. Further studies are needed to determine the 
effect of heterogeneous radiosensitivity on the response of 
individual patients to different regimes of radiotherapy.  
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